Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'
December 27, 2023 1:43 PM ESTTruist Securities analyst Srikripa Devarakonda raised the price target on Cytokinetics (NASDAQ: CYTK) to $86.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Following mgmt conference call on Ph3 SEQUOIA-HCM data and speaking with mgmt postconference call, our conviction around best-in-class potential for... More
Cytokinetics (CYTK) PT Raised to $107 at Oppenheimer, 'We Stay Bullish'
December 27, 2023 1:42 PM ESTOppenheimer analyst Justin Kim raised the price target on Cytokinetics (NASDAQ: CYTK) to $107.00 (from $54.00) while maintaining a Outperform rating.
The analyst comments "Aficamten appears on course toward a best-in-class trajectory in the treatment of oHCM following Phase 3 SEQUOIA results. With the call offering... More
Oppenheimer on Cytokinetics (CYTK): 'We stay bullish'
December 27, 2023 9:23 AM ESTOppenheimer analyst Justin Kim reiterated an Outperform rating and $54.00 price target on Cytokinetics (NASDAQ: CYTK).
The analyst comments "With safety and efficacy for Phase 3 SEQUOIA in tow, aficamten has demonstrated active potency in treating HCM with signs of differentiated safety benefits. Peak VO2... More
Mizuho on Cytokinetics (CYTK): 'Investors will now likely shift the debate back to M&A'
December 27, 2023 9:21 AM ESTMizuho Securities analyst Salim Syed reiterated a Buy rating and $80.00 price target on Cytokinetics (NASDAQ: CYTK).
The analyst comments "This morning, Cytokinetics announced aficamten's Ph3 SEQUOIA-HCM results in obstructive hypertrophic cardiomyopathy (oHCM) patients. The data read very clean -- numerically better on... More
Truist on Cytokinetics (CYTK): 'We See Best In Class Potential for aficamten'
December 27, 2023 9:20 AM ESTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK)
The analyst comments "SEQUOIA-HCM was in line with our expectations. The trial hit as pVO2 improvements, the primary endpoint, were stat sig (p=0.000002) vs. placebo and numerically better vs. Camzyos. Given these data, we see best-in-class... More
B.Riley on Cytokinetics (CYTK): 'Remain Buyers'
December 27, 2023 9:18 AM ESTB.Riley analyst Mayank Mamtani reiterated a Buy rating and $66.00 price target on Cytokinetics (NASDAQ: CYTK).
The analyst comments "On 12/27 BMO, Cytokinetics (CYTKBuy, $66 PT) reported strong top-line pivotal Ph. III SEQUOIA-HCM study (n=282) results of aficamten (afi) in obstructive hypertrophic cardiomyopathy (oHCM); notably... More
